TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

James Bianco, President and Chief Executive Officer of TuHURA Biosciences

“We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda(®) in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months”

James Bianco, President and Chief Executive Officer of TuHURA Biosciences

“Working collaboratively with the FDA, we received clearance to begin our Phase 1b study of TBS-2025, our VISTA-inhibiting antibody, in relapsed/refractory mutNPM1 acute myeloid leukemia (AML), a molecularly defined subset of AML where the presence of VISTA on leukemic cells is associated with poor response to therapy and survival.”

James Bianco, President and Chief Executive Officer of TuHURA Biosciences

“We will have a strong presence again this year at the upcoming American Society of Hematology (ASH) Annual Meeting in December with 3 poster presentations highlighting our Delta Opioid Receptor (DOR) technology. The ASH scientific review committee recognized the importance of our discoveries of the central role the DOR plays in controlling proliferation, recruitment and immunosuppressive capabilities of MDSCs, the body's main cell type for suppressing immune responses leading to acquired resistance to cancer immunotherapies.”

James Bianco, President and Chief Executive Officer of TuHURA Biosciences

“With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events,”